MedTech Strategist, a leading information and investment conferences provider focused exclusively on the rapidly evolving global medical device industry, is led by managing partners and co-editors-in-chief David Cassak and Stephen Levin, along with a seasoned editorial team and staff. With more than 100 years of combined experience, our team provides our community with both breadth and depth in our industry publication, MedTech Strategist, and access to unparalleled connections at our global investment and partnering conferences. In addition, the MedTech Strategist Community Blog complements the strategic medtech industry coverage that our publication is known for, with candid video interviews and short perspective articles focusing on the people and the passionate innovation behind the most exciting trends in the global device space. Think Strategically. Join Our Community. www.medtechstrategist.com
     
  Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in the space. With strategic insight and a proven strategy, we are well-positioned to continue to find unique investments and drive life science innovation for patients. Members of the Lightstone team manage a portfolio of more than 40 medical device and biotechnology companies across the ATV and Morgenthaler legacy funds. The Lightstone team members have been involved in several of the largest, venture-backed life science exits over the last decade including: Acceleron (XLRN), Access Closure, Acclarent, Ardian, Avidia, Cabochon, Calithera (CALA), Five Prime (FPRX), Flex Pharma (FLKS), FoldRx, Hypnion, MicroVention, Plexxikon, Portola (PTLA), Proteolix, Threshold, and Zeltiq (ZLTQ). Lightstone has offices in Boston MA, Boulder CO, Menlo Park CA and Dublin, Ireland
     
  NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With more than $13 billion in committed capital, the firm invests in information technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. NEA’s long track record of successful investing includes more than 195 portfolio company IPOs and more than 320 acquisitions. For additional information, visit www.nea.com
     
  PricewaterhouseCoopers’ (PwC’s) PwC’s Pharmaceutical and Life Sciences Industry Group is dedicated to delivering effective solutions to the complex strategic, operational and financial challenges facing pharmaceutical, biotechnology and medical device companies. We provide industry-focused assurance, tax and advisory services to build public trust and enhance value for our clients and their stakeholders. More than 195,000 people in 157 countries across our network of firms share their thinking, experience and solutions to develop fresh perspectives and practical advice.
     
  Vensana Capital is a venture capital & growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Launched in 2019 by Kirk Nielsen and Justin Klein, Vensana is actively investing in late development and commercial stage companies across the medtech sector, including medical devices, diagnostics, drug delivery, digital health, and tech-enabled services.
     
  Wilson Sonsini Goodrich & Rosati is the premier provider of legal services to life sciences, technology, and growth enterprises worldwide. The firm is nationally recognized as a leader in corporate governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, joint ventures and strategic alliances, and technology licensing and other intellectual property transactions. Over the past two decades, Wilson Sonsini Goodrich & Rosati has developed an integrated life sciences practice specifically focused on addressing the business and legal issues facing life sciences companies. We advise a large number of pharmaceutical, biotechnology, diagnostic, medical device, and healthcare information and services companies at all stages of development. In addition to the new Boston location, Wilson Sonsini Goodrich & Rosati has offices in Austin; Beijing; Brussels; Hong Kong; Los Angeles; New York; Palo Alto; San Diego; San Francisco; Seattle; Shanghai; Washington, D.C.; and Wilmington, DE. For more information, please visit www.wsgr.com